Two phar­ma­cy ben­e­fit man­ag­er stud­ies find in­creas­ing fees and de­clin­ing opin­ions as House con­sid­ers ac­tion

Two re­cent stud­ies about phar­ma­cy ben­e­fit man­agers spot­light de­clin­ing opin­ions of the in­dus­try and grow­ing fees that have shift­ed prof­its away from re­bates.

Both stud­ies land­ed as the House of Rep­re­sen­ta­tives is con­sid­er­ing adding PBM trans­paren­cy to health­care bills. The House was ex­pect­ed to vote on the bill on Mon­day night, Ax­ios re­port­ed, but lat­er re­port­ed it’s been can­celed for now.

The de­clin­ing opin­ion re­port comes from PSG Strate­gies, which has been track­ing PBM cus­tomer sat­is­fac­tion for 26 years. Its 2023 re­port of em­ploy­ers, health plans and health sys­tems finds over­all sat­is­fac­tion at its low­est point in nine years, notch­ing a 7.6 on a scale of one to 10 from not at all sat­is­fied to ex­treme­ly sat­is­fied. The mean re­sult still in­di­cates “mod­er­ate­ly high over­all sat­is­fac­tion,” PSG notes, but it marks an­oth­er year of de­cline and an over­all low point since 2014.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER